Affiliate disclosure
Book titles on this page link to Amazon. As an Amazon Associate, DataField.Dev earns from qualifying purchases — at no additional cost to you.
Chapter 9 — Further Reading
Start with the systematic reviews
Cochrane: "Reduction in saturated fat intake for cardiovascular disease." Freely available in
plain-language summary at cochranelibrary.com.
This is the single most useful document on the chapter's central question. Note three things as you read: the effect size (modest), the certainty rating (moderate at best), and — crucially — how the reviewers handle the comparator. Then compare their conclusion to how it was reported. For: everyone. Read this before you argue with anyone about saturated fat.
Cochrane reviews on omega-3 supplementation for cardiovascular disease. Same site, and the conclusion — little or no benefit from supplementation in general populations — is a useful counterweight to the enthusiasm. For: anyone taking or considering fish oil.
The primary trials
PREDIMED — published in the New England Journal of Medicine, retracted and republished in 2018 after randomization irregularities were identified. Read the republished paper and the retraction notice. It remains the strongest trial evidence for a dietary pattern in this chapter, and the episode is Chapter 2's self-correction example.
The omega-3 quartet: VITAL, ASCEND, REDUCE-IT, and STRENGTH — all published in major journals and all findable. Read REDUCE-IT and STRENGTH together, plus the published correspondence about the mineral oil placebo. This is a live scientific argument being conducted properly, in public, and watching it is more educational than any summary. For: students, clinicians, and anyone who has been told fish oil is settled either way.
The recovered trials: the re-analyses of the Minnesota Coronary Experiment and the Sydney Diet Heart Study, published in the BMJ. Read the papers and at least two critical responses. These are the strongest pieces of evidence complicating the diet-heart hypothesis, and they are genuinely limited — holding both facts at once is the exercise.
On the history — read both sides
The case that the diet-heart hypothesis was oversold:
Nina Teicholz, The Big Fat Surprise (Simon & Schuster, 2014) and Gary Taubes, Good Calories, Bad Calories (Knopf, 2007).
I recommend these genuinely. They document real failures — the low-fat era's collapse, the overconfidence of the guidance, the industry funding problems — and they are the strongest version of the case this chapter argues against. Read them with the Claim Filter in hand, and pay specific attention to how they handle the Seven Countries Study versus the 22-country analysis (§9.4), because it's a good test of whether a source distinguishes a real critique from a garbled one.
The case that it substantially held:
The AHA Presidential Advisory, "Dietary Fats and Cardiovascular Disease" (Circulation, 2017). Freely available. This is the mainstream position stated carefully, with its evidence laid out, and it addresses coconut oil directly. Also read a critical response to it — there are several — and check whether either states the comparator clearly.
On Ancel Keys specifically: the published scholarly accounts of the Seven Countries Study, including material from the study's own long-running research group. Reading the actual design rationale is the fastest way to evaluate the cherry-picking charge for yourself. For: anyone who has repeated that charge, in either direction.
On lipids and ApoB
The European Atherosclerosis Society consensus statements on LDL and atherosclerosis. These lay out the causal case for LDL — cohort, trial, and Mendelian randomization evidence together — more clearly than anything else available, and they're the source for §9.10's "dose × time" framing. For: students and clinicians. This is the evidence people are usually arguing about without having read.
On ApoB versus LDL-C: search for reviews on "apolipoprotein B versus LDL cholesterol risk prediction." The finding that ApoB is the better predictor is increasingly accepted and increasingly reflected in guidelines, and the gap between that and routine practice is the interesting part. For: anyone with high triglycerides and low HDL — which is a lot of people.
On HDL: the history of CETP inhibitors — drugs that raised HDL substantially and failed to reduce cardiovascular events, in some cases increasing harm. This is the cleanest demonstration available that HDL is a marker rather than a lever, and it cost billions to establish. For: anyone still using "good cholesterol" as a mental model.
On trans fats
FDA materials on the 2015 GRAS determination for partially hydrogenated oils (fda.gov) and the
WHO REPLACE initiative (who.int). Both freely available.
Read these as a case study in how long the pipeline from evidence to action actually takes, and what it takes to move it. REPLACE in particular is worth knowing about because industrial trans fats remain a live public health problem in parts of the world where regulation hasn't arrived. For: everyone interested in whether nutrition science ever accomplishes anything. It does, slowly.
On cooking oils
Research on oil oxidative stability under domestic cooking conditions. Search for studies comparing oils heated at realistic household temperatures and durations, measuring oxidation products rather than smoke point. The finding that extra-virgin olive oil performs better than its smoke point predicts is reproducible and consistently surprising to people. For: anyone who has bought an oil because of its smoke point.
On adulteration: reports on olive oil and avocado oil authenticity — this is a genuine and documented problem in both markets, and it's a reason to buy from sources you trust rather than a reason to avoid the oils.
Reference
USDA FoodData Central — fdc.nal.usda.gov. Fatty acid breakdowns for any food. This is where the
"butter is 63% saturated" figures come from, and looking up three or four foods yourself is the fastest
cure for thinking of foods as single-fat-type.
NIH Office of Dietary Supplements fact sheet on omega-3 fatty acids (ods.od.nih.gov).
Even-handed, updated, and clear about where the supplement evidence is weak.
A note on reading this topic
This is the chapter where I most want you to read the opposition, and where the failure mode is symmetric.
If you read only mainstream sources, you'll miss that the low-fat era failed, that the guidance was communicated badly, that industry funding shaped some of the literature, and that the recovered trials are genuinely complicating.
If you read only contrarian sources, you'll come away believing saturated fat has been exonerated, that the LDL hypothesis has collapsed, and that Keys cherry-picked his data — none of which is true, and the last of which is a specific factual claim you can check in an afternoon.
The test that works on both: does the source state the comparator? A source that discusses saturated fat without ever specifying what it's being compared to has not reached §9.5, whatever else it knows — and that test disqualifies a startling proportion of the writing on this topic in both directions.